Roche Holding ( RHHBY ) recently announced survival data from its phase III CLEOPATRA study on Perjeta (pertuzumab). Data from the study showed that Perjeta plus Roche’s existing breast
Merck ( MRK ) recently moved its Alzheimer’s disease candidate, MK-8931, into a phase II/III study (EPOCH). The study will evaluate the safety and efficacy of MK-8931, an oral β-amyloid
FXstreet.com (Barcelona) – Today’s upside in the shared currency remains capped in the proximities of 1.2940, as increasing risk appetite is fueling the ascent. Seems that euro traders have